Gaviscon maker to pay £10 million for antitrust law breach
The UK competition watchdog the Office for Fair Trading has fined Reckitt Benckiser £10.2 million ($16 million) after the company admitted abusing its dominant position when supplying heartburn medicines to the National Health Service
In February, the OFT said that it had sent a Statement of
Objections to the maker of Gaviscon alleging that the company
tried to reduce competition by withdrawing and de-listing its
National Health Service packs of Gaviscon Original Liquid
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.